P3 Health Partners Inc. (PIII) Stock Price & Analysis
P3 Health Partners Inc. (PIII) rose 2.37% to USD 12.54 as of June 10, 2026 at 11:16 UTC, according to Nexqual real-time market data.
PIII last closed at USD 12.25; the session ranged USD 11.23–12.54 on volume of 49,035 shares. Market capitalization is $2.55B, with a 52-week range of USD 1.52–16.89 (NCM). Source: Nexqual, June 10, 2026 at 11:16 UTC.
Key Statistics (as of June 10, 2026 at 11:16 UTC)
| Price | USD 12.54 |
|---|---|
| Change | ▲ 2.37% (up) |
| Previous Close | USD 12.25 |
| Open | USD 11.77 |
| Day Range | USD 11.23 – 12.54 |
| 52-Week Range | USD 1.52 – 16.89 |
| Volume | 49,035 shares |
| Market Cap | $2.55B |
| Exchange | NCM |
Technical Analysis (PIII)
Nexqual's technical model rates PIII "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 11:16 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.17 (neutral) |
| vs SMA50 | Above (USD 5.88) |
| MACD | 1.99 (positive) |
Analyst Ratings (PIII)
Wall Street analysts rate PIII "None" based on 2 analysts, with a mean price target of USD 14 (range USD 14–14), per Nexqual as of June 10, 2026 at 11:16 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 14 |
| High Target | USD 14 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (PIII)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $377.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.32 vs est -3.51 ▲ beat |
| 2025-12-31 | USD -23.02 vs est -9.47 ▼ miss |
| 2025-09-30 | USD -9.67 vs est -6.04 ▼ miss |
| 2025-06-30 | USD -6.23 vs est -4.3 ▼ miss |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
Financials & Fundamentals (PIII)
| Total Revenue | $1.46B |
|---|---|
| Revenue Growth (YoY) | +3.80% |
| Gross Margin | -4.12% |
| Operating Margin | -39.98% |
| Profit Margin | -10.14% |
| ROE | -6952.57% |
| Current Ratio | 0.24 |
| Total Cash | $25.01M |
| Total Debt | $287.28M |
| Free Cash Flow | $16.28M |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
Financial Health Score (PIII)
Nexqual rates P3 Health Partners Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:16 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Critical — Gross margin -4%, operating -40% |
| Balance Sheet | Mixed — $25M cash vs $287M debt |
| Cash Flow | Mixed — FCF $16M, slim 1.1% margin |
| Efficiency | Critical — ROE -6953%, ROA -23.5% |
Ownership (PIII)
| Insider Ownership | +50.64% |
|---|---|
| Institutional Ownership | +7.32% |
| Shares Outstanding | 3.33M |
| Float | 1.42M |
| Short % of Float | +5.44% |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
Leadership (PIII)
P3 Health Partners Inc. is led by Aric Coffman (age 51), CEO, President & Director, per Nexqual as of June 10, 2026 at 11:16 UTC.
| CEO, President & Director | Aric Coffman (age 51) |
|---|---|
| Co-Founder, Chief Medical Officer & Director | Amir Bacchus (age 60) |
| Chief Financial Officer | Leif Pedersen (age 49) |
| Executive VP & COO | William Bettermann |
| Senior Vice President of Technology | Devery Goodey |
Major Backers & Investors (PIII)
Notable institutional backers of P3 Health Partners Inc. include Trinity Financial Advisors LLC, Fidelity, Diversified Trust Company, according to Nexqual as of June 10, 2026 at 11:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Trinity Financial Advisors LLC | 0.81% |
| Fidelity | 0.7% |
| Diversified Trust Company | 0.61% |
| Corient Private Wealth LLC | 0.6% |
| Nine Masts Capital Ltd. | 0.54% |
| HRT Financial LP | 0.45% |
| Susquehanna International Group, LLP | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.24% |
| Geode Capital | 0.78% |
| BlackRock | 0.42% |
Source: Nexqual, June 10, 2026 at 11:16 UTC.
From P3 Health Partners Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed proprietary technology and processes that support our operational programs and clinical insights, including our P3 Technology/Health Hub, which is a proprietary system that aids in the aggregation and analysis of third-party data we collect.
- Using our proprietary technology platform for integrated data reporting, physicians can stratify their patient panels based on risk.
- P3 Technology/Health Hub The backbone of our P3 Care Model is our proprietary technology platform—P3 Technology/Health Hub—which enables physicians, care teams, patients and their family members to engage in the care journey.
- We staff dedicated care managers and care navigators to help ensure end-to-end patient care across the full continuum.
Partnerships
- We believe that allowing them to maintain their independence increases their engagement with population health management practices, which is key to transforming the healthcare system. • Limited collaboration between PCPs and payors.
- We are "family" and we take care of each other with the same intensity as we take care of our patients. ◦ Collaboration " We achieve more when we work as one. " ◦ Service: "We serve others with empathy, purpose, and a commitment to excellence." • Passion: Our heart is our patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCWB | HCW Biologics Inc. | USD 1.18 | ▼ 27.61% |
| SNAL | Snail, Inc. | USD 0.79 | ▲ 3.96% |
| ERNA | Ernexa Therapeutics Inc. | USD 6.8 | ▼ 13.81% |
| TOI | The Oncology Institute, Inc. | USD 4.96 | ▲ 1.85% |
| AKAN | Akanda Corp. | USD 13.76 | ▼ 11.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:16 UTC. This page is informational and not investment advice.